1399-P: Lipoprotein Subfractions and Type 2 Diabetes Incidence in the Mediators of Atherosclerosis in South Asians Living in America (MASALA) and Multiethnic Study of Atherosclerosis (MESA) Cohorts

Abstract

Background: Atherogenic dyslipidemia is prevalent in individuals at risk for type 2 diabetes (T2D) but less is known about composition of lipoprotein subfractions in diverse racial/ethnic groups. We examined associations between lipoprotein subfractions and incident T2D among participants of the MASALA and MESA cohorts. Methods: Adults aged 45-84 years without T2D and with fasting serum, demographic and clinical data at baseline and 2-5 year follow-up were included. Lipoprotein subfractions were measured at baseline using NMR spectrometry on a common platform. LASSO regularized logistic regression models adjusted for age, sex, race/ethnicity, lipid-lowering agents and waist circumference assessed odds of incident T2D with adjustment for multiple comparisons. Results: Analyses included 3839 participants with average age of 62 years, 51% women, mean BMI 28 kg/m2 and 234 incident T2D cases. Triglycerides (TG) in LDL-5, LDL-6 and HDL-3 and HDL-4 were associated with odds of incident T2D and free cholesterol in HDL-1 was inversely associated (Table). There were no interactions by race. Conclusions: TG in small, dense HDL and LDL were positively associated, while free cholesterol in large HDL was inversely related to odds of incident T2D at first follow-up in participants of the MESA and MASALA cohort studies. Disclosure M.D.Gadgil: None. D.M.Herrington: None. S.Singh: None. N.R.Kandula: None. A.M.Kanaya: None. Funding National Institute of Diabetes and Digestive and Kidney Diseases (1K23DK119404-01A1); National Heart, Lung, and Blood Institute/National Center Research Resources/National Center for Advancing Translational Sciences (R01HL093009); National Institutes of Health (UL1RR024131); Medical Research Council/National Institute for Health and Care Research (NC-PC-12025); National Institute for Health and Care Research Imperial Biomedical Research Centre; National Heart, Lung, and Blood Institute (75N92020D00001, HHSN268201500003I, N01HC-95159, 75N92020D00005, N01HC-95160, 75N92020D00002, N01HC95161, 75N92020D00003, N01HC95162, 75N92020D00006, N01HC95163, 75N92020D00004, N01HC95164, 75N92020D00007, N01HC95165, N01HC95166, N01HC95167, N01HC95168, N01HC95169); National Center for Advancing Translational Sciences (UL1TR000040, UL1TR001079, UL1TR001420)